Pregabalin Tablet, Film Coated, Extended Release
Product Images NDC 72888-051

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72888-051). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advagen Pharma Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin Extended-release Tablets, 165 mg (NDC 72888-050-30)

Label for Pregabalin Extended-Release Tablets 165 mg by Advagen Pharma Ltd., containing 30 film-coated extended-release tablets. Distributed by Advagen Pharma Limited, Plainsboro, NJ, and manufactured by Rubicon Research Private Limited, India. Includes storage instructions, dosage note, and child-resistant container warning. Features barcode and a yellow highlighted product name and strength area.*

FDA Label Image

Pregabalin Extended-release Tablets, 330 mg (NDC 72888-051-30)

Label for Pregabalin Extended-Release Tablets 330 mg, film-coated tablets for oral use. The label states each tablet contains 330 mg of Pregabalin, USP. The product is distributed by Advagen Pharma Limited, Plainsboro, NJ, and manufactured by Rubicon Research Private Limited, India. Packaging contains 30 tablets. Includes storage instructions, child-resistant container warning, Rx only designation, and a barcode.*

FDA Label Image

Pregabalin Extended-release Tablets, 82.5 mg (NDC 72888-049-30)

Label for Pregabalin Extended-Release Tablets 82.5 mg by Advagen Pharma Ltd. The label shows the strength as 82.5 mg per tablet in a blue box. The product is film-coated, extended-release tablets, packaged as 30 tablets for oral use. Manufacturing information lists Rubicon Research Private Limited in India. Storage instructions and medication guide dispensing notice are also included.*

FDA Label Image

Pregabalin Extended-release Tablets Equation (Pregabalin Er Tab Equation)

An illustration showing the formula for calculating creatinine clearance (CLCr), which uses age in years, weight in kilograms, serum creatinine in mg/dL, and includes a multiplication factor of 0.85 for female patients.*

FDA Label Image

Pregabalin Extended-release Tablets Figure 1 (Pregabalin Er Tab Figure1)

A line graph comparing percent of patients improved versus percent improvement in pain from baseline for Pregabalin and placebo. It depicts two curves: a solid line for Pregabalin and a dashed line for placebo, showing the relationship between pain improvement percentage and patient response rates.*

FDA Label Image

Pregabalin Extended-release Tablets Structure (Pregabalin Er Tab Structure)

Chemical structure diagram of Pregabalin, showing its molecular arrangement including functional groups such as carboxylic acid (CO2H) and amine (NH2). This illustrates the active pharmaceutical ingredient Pregabalin used in oral extended-release tablets by Advagen Pharma Ltd.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.